UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031667
Receipt number R000036168
Scientific Title Clinical Safety and Effectiveness of Tolvaptan for patients with heart falure
Date of disclosure of the study information 2018/03/11
Last modified on 2023/01/14 09:01:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical Safety and Effectiveness of Tolvaptan for patients with heart falure

Acronym

Clinical Safety and Effectiveness of Tolvaptan

Scientific Title

Clinical Safety and Effectiveness of Tolvaptan for patients with heart falure

Scientific Title:Acronym

Clinical Safety and Effectiveness of Tolvaptan

Region

Japan


Condition

Condition

heart failure

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluate the efficacy and safety of tolvaptan for heart failure patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Clinical adverse events in-hospital, at 6 month follow-up, at 12 month follow-up, and at 24 month follow-up
(all-cause death, cardiovascular death, worsened heart failure, cerebral infarction, intubation, fetal arrhythmia, discharge postponement, rehospitalization)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

110 years-old >

Gender

Male and Female

Key inclusion criteria

acute heart failure cases who admitted at Teikyo University hospital and had oral tolvaptan

Key exclusion criteria

none

Target sample size

700


Research contact person

Name of lead principal investigator

1st name Kataoka
Middle name
Last name Akihisa

Organization

Teikyo University

Division name

Department of Medicine

Zip code

173-8606

Address

2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan

TEL

+81-3-3964-1211

Email

kataoaki@sd5.so-net.ne.jp


Public contact

Name of contact person

1st name Kataoka
Middle name
Last name Akihisa

Organization

Teikyo University Hospital

Division name

Department of Medicine

Zip code

173-8606

Address

2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan

TEL

+81-3-3964-1211

Homepage URL


Email

kataoaki@sd5.so-net.ne.jp


Sponsor or person

Institute

Teikyo University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Teikyo University IRB

Address

2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan

Tel

03-3964-7256(42203)

Email

turb-office@teikyo-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 03 Month 11 Day


Related information

URL releasing protocol

https://link.springer.com/article/10.1007/s00380-021-01934-8?fbclid=IwAR3xITQKlaGde3kTcRVD7hpdzd6hSR

Publication of results

Published


Result

URL related to results and publications

https://link.springer.com/article/10.1007/s00380-021-01934-8?fbclid=IwAR3xITQKlaGde3kTcRVD7hpdzd6hSR

Number of participants that the trial has enrolled

317

Results

After multiple adjustments, there were no significant differences for overall survival and rehospitalization between the groups.

Results date posted

2021 Year 09 Month 12 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

The patients were divided into 2 groups: those who had significant FMR and those who did not at discharge.

Participant flow

This is a retrospective, single-center, observational study. Patients who were hospitalized due to congestive HF defined according to the Framingham criteria at our institution during two periods: between May 2011 and April 2012 (before TLV was approved) and between May 2017 and April 2018 (after TLV was approved) were enrolled in the study.

Adverse events

N/A

Outcome measures

Primary objective was to evaluate the efficacy of TLV to reduce the all-cause mortality and rehospitalization due to worsening HF in patients with significant FMR during one year of follow-up. Our secondary objective was to evaluate the same outcomes in patients without significant FMR.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 11 Month 02 Day

Date of IRB

2017 Year 11 Month 02 Day

Anticipated trial start date

2017 Year 11 Month 02 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Study design: observation study

Study (enrolment) duration: Nov 2, 2019 to Mar 31, 2018

Object recruitment: acute heart failure cases who admitted at Teikyo University hospital and had oral tolvaptan

Observation item: Clinical adverse events in-hospital, at 6 month follow-up, at 12 month follow-up, and at 24 month follow-up
(all-cause death, cardiovascular death, worsened heart failure, cerebral infarction, intubation, fetal arrhythmia, discharge postponement, rehospitalization)


Management information

Registered date

2018 Year 03 Month 11 Day

Last modified on

2023 Year 01 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036168


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name